Skip to main content
Top
Published in: PharmacoEconomics 10/2014

01-10-2014 | Original Research Article

Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcomes

Authors: Zafar Zafari, Kristian Thorlund, J. Mark FitzGerald, Carlo A. Marra, Mohsen Sadatsafavi

Published in: PharmacoEconomics | Issue 10/2014

Login to get access

Abstract

Objective

To evaluate the impact of using two evidence-synthesis paradigms, pairwise meta-analysis (PMA) vs. network meta-analysis (NMA), on the expected value of information (EVI) outcomes, using pharmacotherapy of chronic obstructive pulmonary disease as a case study.

Methods

Bayesian random-effects PMAs were performed for each pharmacotherapy vs. placebo, and a Bayesian random-effects NMA was performed combining both placebo-controlled and head-to-head trials. Both provided comparative rate ratio (RR) estimates between each pharmacotherapy vs. placebo. A Markov model was developed to project costs and quality-adjusted life-years of five commonly used treatments for chronic obsructive pulmonary disorder. RRs for the treatment effect compared with placebo derived using PMA and NMA were used alongside values from the literature to populate the model. In addition to standard cost-effectiveness outputs, we calculated and compared the expected value of perfect information (EVPI) and the expected value of partial perfect information (EVPPI) for treatment effects, for comparisons that included all or a subset of treatments.

Results

The network of evidence included five different treatments, compared in 19 randomized controlled trials (RCTs), which in total included 28,172 individuals. The cost-effectiveness outcomes were similar between the two evidence-synthesis paradigms. The individual EVPI for all treatments was Can$1,262 for PMA-based analyses and Can$572 for NMA-based analyses. For all comparisons involving two, three, or four treatments, the comparison with the highest EVPI was different between the two methods. Similarly, the choice of PMA or NMA had resulted in substantially different EVPPI rankings.

Conclusion

Our case study shows that the choice of PMA or NMA can have significant effects on the EVI results. Under comparable conditions, the incorporation of more evidence in the NMA most likely increases the precision of estimates and therefore is likely to result in lower EVI outcomes. As our study demonstrates, the difference in EVI outcomes can be substantial, potentially affecting the decision to conduct research and the design of future research.
Appendix
Available only for authorised users
Literature
1.
go back to reference Drummond M, O’Brien B, Stoddart G, Torrance G. Methods for the economic evaluation of health care programmes. UK: Oxford University Press; 2005. Drummond M, O’Brien B, Stoddart G, Torrance G. Methods for the economic evaluation of health care programmes. UK: Oxford University Press; 2005.
2.
go back to reference Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ. 1999;18(3):341–64.PubMedCrossRef Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ. 1999;18(3):341–64.PubMedCrossRef
3.
go back to reference Eckermann S, Willan AR. Expected value of information and decision making in HTA. Health Econ. 2007;16(2):195–209.PubMedCrossRef Eckermann S, Willan AR. Expected value of information and decision making in HTA. Health Econ. 2007;16(2):195–209.PubMedCrossRef
4.
go back to reference Sculpher M, Claxton K, Drummond M, McCabe C. Whether trial-based economic evaluation for health care decision making? Health Econ. 2006;15(7):677–87.PubMedCrossRef Sculpher M, Claxton K, Drummond M, McCabe C. Whether trial-based economic evaluation for health care decision making? Health Econ. 2006;15(7):677–87.PubMedCrossRef
5.
go back to reference Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 1997;6(3):217–27.PubMedCrossRef Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 1997;6(3):217–27.PubMedCrossRef
6.
go back to reference Caldwell DM, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331(7521):897–900.PubMedCrossRefPubMedCentral Caldwell DM, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331(7521):897–900.PubMedCrossRefPubMedCentral
8.
go back to reference Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Mak. 2013;33(5):607–17.CrossRef Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Mak. 2013;33(5):607–17.CrossRef
9.
go back to reference Cooper NJ, Peters J, Lai MCW, Juni P, Wandel S, Palmer S, et al. How valuable are multiple treatment comparison methods in evidence-based health-care evaluation? Value Health. 2011;14(2):371–80.PubMedCrossRef Cooper NJ, Peters J, Lai MCW, Juni P, Wandel S, Palmer S, et al. How valuable are multiple treatment comparison methods in evidence-based health-care evaluation? Value Health. 2011;14(2):371–80.PubMedCrossRef
10.
go back to reference Thorlund K, Zafari Z, Druyts E, Mills EJ, Sadatsafavi M. The impact of incorporating Bayesian network meta-analysis in cost-effectiveness analysis—a case study of pharmacotherapies for moderate to severe COPD. Cost Eff Resour Alloc. 2014;12(1):8. Thorlund K, Zafari Z, Druyts E, Mills EJ, Sadatsafavi M. The impact of incorporating Bayesian network meta-analysis in cost-effectiveness analysis—a case study of pharmacotherapies for moderate to severe COPD. Cost Eff Resour Alloc. 2014;12(1):8.
11.
go back to reference Mills EJ, Druyts E, Ghement I, Puhan MA. Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clin Epidemiol. 2011;28(3):107–29.CrossRef Mills EJ, Druyts E, Ghement I, Puhan MA. Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clin Epidemiol. 2011;28(3):107–29.CrossRef
12.
go back to reference Lunn D, Thomas A, Best N, Spiegelhalter D. WinBUGS: a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2000;10:325–37.CrossRef Lunn D, Thomas A, Best N, Spiegelhalter D. WinBUGS: a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2000;10:325–37.CrossRef
13.
go back to reference Buist AS, Vollmer WM, Sullivan SD, Weiss KB, Lee TA, Menezes AM, et al. The burden of obstructive lung disease initiative (BOLD): rationale and design. COPD. 2005;2(2):277–83.PubMedCrossRef Buist AS, Vollmer WM, Sullivan SD, Weiss KB, Lee TA, Menezes AM, et al. The burden of obstructive lung disease initiative (BOLD): rationale and design. COPD. 2005;2(2):277–83.PubMedCrossRef
15.
go back to reference R Development Core Team. R: A language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2011 [cited 2009 Nov 16]. http://www.r-project.org/. R Development Core Team. R: A language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2011 [cited 2009 Nov 16]. http://​www.​r-project.​org/​.
16.
go back to reference Barton GR, Briggs AH, Fenwick EAL. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health. 2008;11(5):886–97.PubMedCrossRef Barton GR, Briggs AH, Fenwick EAL. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health. 2008;11(5):886–97.PubMedCrossRef
17.
go back to reference Brennan A, Kharroubi S, O’Hagan A, Chilcott J. Calculating partial expected value of perfect information via Monte Carlo sampling algorithms. Med Decis Mak. 2007;27(4):448–70.CrossRef Brennan A, Kharroubi S, O’Hagan A, Chilcott J. Calculating partial expected value of perfect information via Monte Carlo sampling algorithms. Med Decis Mak. 2007;27(4):448–70.CrossRef
18.
go back to reference Jalal H, Dowd B, Sainfort F, Kuntz KM. Linear regression metamodeling as a tool to summarize and present simulation model results. Med Decis Mak. 2013;33(7):880–90.CrossRef Jalal H, Dowd B, Sainfort F, Kuntz KM. Linear regression metamodeling as a tool to summarize and present simulation model results. Med Decis Mak. 2013;33(7):880–90.CrossRef
19.
go back to reference Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–63.PubMedCrossRefPubMedCentral Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–63.PubMedCrossRefPubMedCentral
20.
go back to reference Mills EJ, Ioannidis JPA, Thorlund K, Schünemann HJ, Puhan MA, Guyatt GH. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA. 2012;308(12):1246–53.PubMedCrossRef Mills EJ, Ioannidis JPA, Thorlund K, Schünemann HJ, Puhan MA, Guyatt GH. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA. 2012;308(12):1246–53.PubMedCrossRef
21.
go back to reference Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14(4):417–28.PubMedCrossRef Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14(4):417–28.PubMedCrossRef
22.
go back to reference Ades A, Claxton K, Sculpher M. Evidence synthesis, parameter correlation and probabilistic sensitivity analysis. Health Econ. 2006;15(4):373–81.PubMedCrossRef Ades A, Claxton K, Sculpher M. Evidence synthesis, parameter correlation and probabilistic sensitivity analysis. Health Econ. 2006;15(4):373–81.PubMedCrossRef
23.
go back to reference Cooper N, Sutton A, Abrams K, Turner D, Wailoo A. Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach. Health Econ. 2004;13(3):203–26.PubMedCrossRef Cooper N, Sutton A, Abrams K, Turner D, Wailoo A. Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach. Health Econ. 2004;13(3):203–26.PubMedCrossRef
25.
go back to reference Hoogendoorn M, Rutten-van Mölken MPMH, Hoogenveen RT, van Genugten MLL, Buist AS, Wouters EFM, et al. A dynamic population model of disease progression in COPD. Eur Respir J. 2005;26(2):223–33.PubMedCrossRef Hoogendoorn M, Rutten-van Mölken MPMH, Hoogenveen RT, van Genugten MLL, Buist AS, Wouters EFM, et al. A dynamic population model of disease progression in COPD. Eur Respir J. 2005;26(2):223–33.PubMedCrossRef
26.
go back to reference Spencer M, Briggs A, Grossman R, Rance L. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics. 2005;23(6):619–37.PubMedCrossRef Spencer M, Briggs A, Grossman R, Rance L. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics. 2005;23(6):619–37.PubMedCrossRef
28.
go back to reference Najafzadeh M, Marra CA, Lynd LD, Sadatsafavi M, FitzGerald JM, McManus B, et al. Future impact of various interventions on the burden of COPD in Canada: a dynamic population model. PLoS One. 2012;7(10):e46746.PubMedCrossRefPubMedCentral Najafzadeh M, Marra CA, Lynd LD, Sadatsafavi M, FitzGerald JM, McManus B, et al. Future impact of various interventions on the burden of COPD in Canada: a dynamic population model. PLoS One. 2012;7(10):e46746.PubMedCrossRefPubMedCentral
29.
go back to reference Chapman KR, Bourbeau J, Rance L. The burden of COPD in Canada: results from the Confronting COPD survey. Respir Med. 2003;97(Suppl C):S23–31.PubMedCrossRef Chapman KR, Bourbeau J, Rance L. The burden of COPD in Canada: results from the Confronting COPD survey. Respir Med. 2003;97(Suppl C):S23–31.PubMedCrossRef
30.
go back to reference MIMS. MIMS: Prescription drug database and drug prescription guide. 2012. MIMS. MIMS: Prescription drug database and drug prescription guide. 2012.
Metadata
Title
Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcomes
Authors
Zafar Zafari
Kristian Thorlund
J. Mark FitzGerald
Carlo A. Marra
Mohsen Sadatsafavi
Publication date
01-10-2014
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 10/2014
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-014-0179-1

Other articles of this Issue 10/2014

PharmacoEconomics 10/2014 Go to the issue